Related Experiment Video

Updated: Sep 27, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K

Treatment of Giant Cell Arteritis (GCA)

Alexis Régent1,2, Luc Mouthon1,2

  • 1Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Systémiques Rares d'Ile de France, APHP-CUP, Hôpital Cochin, F-75014 Paris, France.

Journal of Clinical Medicine
|April 12, 2022
PubMed

Insights

Giant cell arteritis (GCA) treatment is evolving beyond glucocorticoids (GCs). New biologic therapies targeting specific pathways show promise for improving outcomes and reducing GC toxicity in patients over 50.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Giant cell arteritis (GCA) is the most common large-vessel vasculitis in individuals over 50.
  • Glucocorticoids (GCs) are the primary treatment but are associated with significant adverse events in this population.
  • Limited efficacy of traditional immunosuppressants necessitates exploring novel therapeutic strategies.

Purpose of the Study:

  • To review the scientific rationale for emerging targeted therapies in GCA.
  • To discuss the therapeutic strategies and optimal application of these new agents.
  • To evaluate the potential of biologics in improving GCA management and reducing GC burden.

Main Methods:

  • Review of current literature on GCA pathophysiology and treatment.
  • Analysis of clinical trial data for novel therapeutic agents.
  • Discussion of the benefit/risk profiles of various treatment options.

Main Results:

  • Tocilizumab (anti-IL-6 receptor inhibitor) has demonstrated significant benefits in reducing GC dosage and preventing relapses.
  • Several other targeted therapies, including anti-IL-12/23, anti-IL-17, and JAK inhibitors, are under investigation.
  • Mavrilimumab, ustekinumab, and abatacept have shown promising results in Phase 2 trials.

Conclusions:

  • While significant progress has been made, the optimal use of each new therapy for GCA requires further definition.
  • Targeted therapies offer potential for improved efficacy and safety compared to traditional treatments.
  • Future research should focus on defining specific indications and treatment strategies for novel GCA therapies.

Keywords:
biologicsgiant cell arteritisglucocorticoidsimmunosuppressanttreatment

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

367
Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices07:21

Microsurgical Creation of Giant Bifurcation Aneurysms in Rabbits for the Evaluation of Endovascular Devices

Published on: September 8, 2023

800

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
717
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
42
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
265
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
38
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
54
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
270